Poly Medicure Limited
Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11-33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923

POLYMED

Date: 07 August, 2026

Scrip Code: - 531768

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 07th August, 2026, at Jaipur Marriott Hotel , Ashram Marg, Near Jawahar Circle, Rajasthan, Jaipur-302015, India approved the following businesses:

1. **Financial Results**

Unaudited Financial Results (Consolidate & Standalone) for the First quarter ended on 30th June 2026.

A signed copy of the above Financial Results (Standalone & Consolidated) along with Auditors' Review Reports thereon is attached herewith as **"Annexure – A"**

2. **Grant of Stock Options**

Nomination & Remuneration Committee, held on today i.e. August 07, 2026 approved grant of 1,476 (One Thousand Four Hundred Seventy Six Only) Stock Options under the Poly Medicure Limited Employee Stock Option Scheme 2020, to eligible employees.

The disclosure(s) as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and December 31, 2024, for the above mentioned ESOP Grant is enclosed herewith as **"Annexure – B".**

3. **Allotment of Stock Options**

Nomination & Remuneration Committee, held on today i.e. August 07, 2026 approved Allotment of 1,975 Equity Shares having face value of Rs. 5/ -each to its eligible employees of the Company who has exercised the option Under its Employee Stock Option Scheme, 2020.

Consequent to this allotment, the paid-up Equity Share Capital of the Company stands increased to Rs. 50,68,07,325 (consisting of 10,13,61,465 equity shares of face value of Rs. 5 each) from Rs. 50,67,97,450 (consisting of 10,13,59,490 equity shares of face value of Rs. 5 each).

The details as required under Regulation 10(c) SEBI (Share Based Employee Benefits Sweat Equity) Regulations, 2021 is Enclosed as "**Annexure -C**"

4. **Re-appointment of Cost Auditors**

Re-appointment of M/s Jai Prakash & Company as the Cost Auditors of the Company for the Financial Year 2026-27.

The information in terms of Regulation 30 read with Schedule III - Para A of Part A of the Listing Regulations (as applicable) and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as "**Annexure – D**".

5. **Resignation of Deputy Company Secretary, KMP**

Mr. Ravi Prakash has tendered his resignation from the position of Deputy Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company to pursue an alternate career opportunities outside the Organization. He tendered his resignation vide letter dated 21 July 2026 and will be relieved from his responsibilities with effect from close of business hours on 10 August 2026.

The information in terms of Regulation 30 read with Schedule III - Para A of Part A of the Listing Regulations (as applicable) and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as "**Annexure-E**"

The Meeting was started at 01.15 P.M. and concluded on 2:20 P.M.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,
Yours Sincerely

For **Poly Medicure Limited**

AVINASH CHANDRA

Digitally signed by AVINASH CHANDRA
Date: 2026.08.07 14:54:41 +05'30'

Avinash Chandra
Company Secretary
M. No. A32270

Annexure-A

POLY MEDICURE LIMITED

POLYMED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020

Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ in lacs except per share data)

	Particulars	Standalone			Consolidated			Standalone	Consolidated
		Quarter Ended			Quarter Ended			Year Ended	Year Ended
		30.06.2026	31.03.2026	30.06.2025	30.06.2026	31.03.2026	30.06.2025	31.03.2026	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	**Income**								
a	Revenue from operations	43,109.95	44,301.49	38,404.67	52,537.55	53,451.14	40,321.07	1,66,246.48	1,87,525.92
b	Other income	2,864.96	1,512.19	4,109.55	3,340.90	1,775.65	4,169.09	11,991.77	12,008.22
	Total income (A)	**45,974.91**	**45,813.68**	**42,514.22**	**55,878.45**	**55,226.79**	**44,490.16**	**1,78,238.25**	**1,99,534.14**
2	**Expenses**								
a	Cost of materials consumed	15,274.60	13,696.45	12,874.86	18,387.50	15,507.80	14,107.35	53,885.50	59,938.70
b	Purchases of stock-in-trade	177.12	136.08	85.85	267.46	138.42	85.85	503.71	506.05
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,172.15)	953.25	(755.28)	(4,680.08)	2,169.97	(1,470.17)	(1,339.64)	(763.63)
d	Employee benefits expense	8,890.80	7,810.19	6,921.40	12,690.29	12,614.10	7,439.74	31,314.62	40,225.59
e	Research and development expenses	788.01	766.14	726.30	789.11	674.29	728.45	2,980.30	2,987.59
f	Finance cost	438.46	389.20	281.38	650.14	640.86	295.01	1,343.32	1,829.07
g	Depreciation and amortisation expense	2,647.00	2,550.70	2,295.49	3,625.28	3,823.20	2,337.02	9,789.82	11,551.66
h	Other expenses	9,067.13	8,831.05	8,377.81	12,573.51	11,306.83	8,804.71	34,291.11	40,399.97
	Total expenses (B)	**34,110.97**	**35,133.06**	**30,807.81**	**44,303.21**	**46,875.47**	**32,327.96**	**1,32,768.74**	**1,56,675.00**
3	**Profit before share of profit of associate, exceptional item and tax (A-B)**	**11,863.94**	**10,680.62**	**11,706.41**	**11,575.24**	**8,351.32**	**12,162.20**	**45,469.51**	**42,859.14**
4	Share of Profit of an associate	-	-	-	155.33	170.90	132.43	-	568.37
	Profit before exceptional item and tax	**11,863.94**	**10,680.62**	**11,706.41**	**11,730.57**	**8,522.22**	**12,294.63**	**45,469.51**	**43,427.51**
5	**Exceptional item**								
	Impact of Labour Codes	-	-		-	-		680.40	680.40
6	**Profit before tax**	**11,863.94**	**10,680.62**	**11,706.41**	**11,730.57**	**8,522.22**	**12,294.63**	**44,789.11**	**42,747.11**
7	Tax expense								
a	Current tax	2,506.74	2,323.31	2,130.98	2,816.11	2,524.29	2,206.81	9,657.70	10,115.84
b	Deferred tax	543.91	275.29	782.54	386.07	(526.02)	779.53	1,502.75	528.11
c	Earlier year taxes	0.96	19.85	-	0.96	19.85	-	30.17	30.17
	Total tax expense	**3,051.61**	**2,618.45**	**2,913.52**	**3,203.14**	**2,018.12**	**2,986.34**	**11,190.62**	**10,674.12**
8	**Profit after tax**	**8,812.33**	**8,062.17**	**8,792.89**	**8,527.43**	**6,504.10**	**9,308.29**	**33,598.49**	**32,072.99**
9	**Other comprehensive income**								
	Items that will not be reclassified to profit or loss :								
	Remeasurements of defined benefit obligations	(90.94)	83.97	(117.32)	(90.94)	83.97	(117.32)	30.23	30.23
	Tax impacts on above	22.89	(21.14)	29.53	22.89	(21.14)	29.53	(7.61)	(7.61)
	Items that will be reclassified to profit or loss in subsequent period:								
	Exchange differences on translation of financial statements of foreign Subsidiaries	-	-	-	63.73	2,426.97	19.07	-	4,625.97
	Tax impacts on above				-	-	-		-
	Total other comprehensive income	**(68.05)**	**62.83**	**(87.79)**	**(4.32)**	**2,489.80**	**(68.72)**	**22.62**	**4,648.59**
10	**Total comprehensive income (comprising profit after tax and other comprehensive income after tax)**	**8,744.28**	**8,125.00**	**8,705.10**	**8,523.11**	**8,993.90**	**9,239.57**	**33,621.11**	**36,721.58**
11	**Net profit attributable to:**								
	Equity holders of the parent		-	-	**8,602.52**	**6,629.19**	**9,308.29**	-	**32,213.96**
	Non-controlling interests		-	-	(75.09)	(125.09)	-		(140.97)
12	**Other comprehensive income attributable to:**								
	Equity holders of the parent	-	-	-	**(4.35)**	**2,492.99**	**(68.72)**	-	**4,651.68**
	Non-controlling interests	-	-	-	0.03	(3.19)	-		(3.09)

DOOGAR & ASSOCIATES FRN: 0005...N New Delhi Chartered Accountants

POLY MEDICURE LIMITED New Delhi

13	**Total comprehensive income attributable to:**								
	Equity holders of the parent	-	-	-	**8,598.17**	**9,122.18**	**9,239.57**	-	**36,865.64**
	Non-controlling interests	-	-	-	(75.06)	(128.28)	-	-	(144.06)
14	Paid-up equity share capital (Face Value of ₹ 5 each)	5,067.97	5,067.97	5,066.29	5,067.97	5,067.97	5,066.29	5,067.97	5,067.97
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				-	-	-	3,00,203.27	3,05,549.30
16	Earnings per share (Quarterly not annualised) :								
	Basic (₹)	8.69	7.95	8.68	8.49	6.54	9.19	33.15	31.79
	Diluted (₹)	8.68	7.95	8.67	8.48	6.53	9.17	33.12	31.75

POLY MEDICURE LIMITED ★ New Delhi

DOOGAR & ASSOCIATES ★ FRN : 000561N ★ Chartered Accountants ★ New Delhi

Notes:

1 The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 7th August, 2026 and have also been limited reviewed by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review report on these standalone and consolidated financial results.

2 The standalone and consolidated financial results have been prepared in accordance with the principles and procedures of Indian Accounting Standards ("Ind AS") as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013.

3 The consolidated financial results of the Company and its foreign subsidiaries/Indian subsidiary ("Group") and associate have been prepared as per IND AS 110 "Consolidated Financial Statements" and IND AS 28 on "Investment in Associates". The entities whose limited reviewed and management certified financial statements have been included in consolidated financial statements are as annexed.

4 In line with the provisions of Ind AS 108 "Operating Segments" and on the basis of review of operations being done by the management of the Company, the operations of the group falls under medical devices, which is considered to be the only reportable segment by the management.

5 During the quarter ended 30th June, 2026, Polymed Brazil LTDA, a wholly owned subsidiary company has acquired 100% equity in Medyneo Comercio De Produtos Para Saude LTDA at a total consideration of ₹ 34.08 lacs effective from 29th April, 2026.

6 The Hon'ble NCLT of Allahabad has approved the resolution plan submitted by the Company for Himalayan Mineral Waters Private Limited (Target Company) vide Order dated 12th August, 2025 as resolution applicant under corporate insolvency resolution process of Insolvency and Bankruptcy Code (IBC Code) 2016. During the quarter ended 30th June, 2026, upon suspension of the monitoring committee, the Company has assumed control in accordance with Ind AS 110 over the operations of the target company, however change in directorship and change in shareholding is pending as at the date of financial statements, accordingly target company has become the wholly owned subsidiary of the Company and profit and loss statement for the period ended 30th June, 2026 have been consolidated in consolidated financial statements.

7 During the previous year ended 31st March, 2025, the Company had issued 53,19,148 equity shares of ₹ 5/- each at premium of ₹ 1,875/- each (issue price per share ₹ 1,880/- each) amounting to ₹ 99,999.98 lacs to Qualified Institutional Investors on QIP basis and allotment was completed on 22nd August, 2024. The proceeds of QIP have been utilized as per objects of issue and the unutilised amount of ₹ 46,505.35 lacs have temporarily been invested in liquid mutual funds/FD/bonds and balance amount in QIP account is ₹ 7.10 lacs.

8 During the quarter ended 30th June, 2026, 17,500 equity shares at a face value of ₹ 5/- have been granted to eligible employees in pursuance of Employees Stock Option Scheme 2020 at an exercise price of ₹ 100/- per share.

9 The financial results include the results for the quarter ended March 31,2026 being the balancing figures between the audited figures in respect of full financial year ended 31st March 2026 and the published unaudited year to date figures upto the third quarter of the previous financial year.

10 Previous period figures have been regrouped wherever necessary to conform to the current year classification.

11 The unaudited results of Poly Medicure Limited for the quarter ended 30th June 2026 are available on our website, www.polymedicure.com and on the Stock Exchange website www.nseindia.com and www.bseindia.com.

POLY MEDICURE LIMITED ★ New Delhi

Place : Jaipur
Date : 7th August 2026

Himanshu Baid
Managing Director

DOOGAR & ASSOCIATES ★ FRN : 000561N ★ New Delhi ★ Chartered Accountants

List of entities included in the consolidated financial statements for the quarter ended 30th June, 2026 are as under:

Sr. No.	Name of the Company	Country of Incorporation	Holding as on June 30, 2026	Holding as on March 31, 2026
	Parent Company			
1	Poly Medicure Limited			
	Subsidiary			
2	Plan 1 Health India Private Limited[1]	India	100%	100%
3	Poly Medicure (Laiyang) Company Limited[1]	China	100%	100%
4	Poly Medicure B.V.[1]	Netherlands	100%	100%
5	Polymed Brazil LTDA[1]	Brazil	100%	100%
6	Himalayan Mineral Waters Private Limited[1]	India	-	-
	Step - subsidiary			
7	Plan 1 Health SRL[2]	Italy	100%	100%
8	Risor Holding B.V.[2]	Netherlands	90%	90%
9	Wellinq Medical B.V.[3]	Netherlands	100%	100%
10	Pendracare Holding B.V.[3]	Netherlands	100%	100%
11	Pendracare Vascular B.V.[4]	Netherlands	100%	100%
12	Pendracare International B.V.[4]	Netherlands	100%	100%
13	Medistream SA[2]	Switzerland	100%	100%
14	Citieffe SRL[5]	Italy	100%	100%
15	Citieffe Inc.[6]	USA	100%	100%
16	Citieffe De.[6]	Mexico	100%	100%
17	Poly Health Inc.[2]	USA	100%	100%
18	Poly Health Limited[2]	UK	100%	100%
19	Medyneo Comercio De Produtos Para Saude LTDA[7]	Brazil	100%	-
	Associate			
20	Ultra For Medical Products Company (Ultra Med)	Egypt	23%	23%

[1] Wholly-owned subsidiary of Poly Medicure Limited
[2] Wholly-owned subsidiary of Poly Medicure B.V.
[3] Wholly-owned subsidiary of Risor Holding B.V.
[4] Wholly-owned subsidiary of Pendracare Holding B.V.
[5] Wholly-owned subsidiary of Medistream SA
[6] Wholly-owned subsidiary of Citieffe SRL
[7] Wholly-owned subsidiary of Polymed Brazil LTDA

POLY MEDICURE LIMITED New Delhi

POLY MEDICURE LI New D

DOOGAR & ASSOCIATES
Chartered Accountants

Independent Auditors' Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
Board of Directors
Poly Medicure Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020

We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicure Limited ("the company") for the quarter ended 30th June 2026 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Attention is drawn to the fact that the figures for the three months period ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm Registration No. 0005
DOOGAR & ASSOCIATES FRN: 000561N New Delhi Chartered Accountants
Madhusudan Agarwal
Partner
Membership No. 086580
UDIN: 26086580OZSXYB7748

Place: Jaipur
Date: 07 August 2026

13, Community Centre, East of Kailash, New Delhi - 110065
E-mail : client@doogar.com, admin@doogar.com, Website : www.doogar.com
Ph. : 011-46579759, 41051966, 47037656
Branches at : Mumbai and Agra

DOOGAR & ASSOCIATES
Chartered Accountants

Independent Auditors' Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
Board of Directors
Poly Medicure Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Poly Medicure Limited (" Parent") and its subsidiaries (the parent and its subsidiaries together referred to as 'the group') and its share of the profit after tax of its associate for the quarter ended 30th June 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019('the Circular').

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Regulation, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the statement.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. We did not review the financial results of 2 foreign subsidiaries namely Poly Medicure (Laiyang) Co. Limited, China and Polymed Brazil LTDA (consolidated) and one wholly owned subsidiary incorporated in India namely Himalayan Mineral Waters Private Limited included in the consolidated unaudited financial results, whose financial results without elimination reflects total revenue of Rs. 159.68 Lacs, total net profit/ (loss) after tax of Rs. (181.56) Lacs and total comprehensive income/ (loss) of Rs. (181.56) lacs, for the quarter ended 30th June 2026, as considered in the consolidated unaudited financial results.
   The consolidated unaudited financial results also include the Group's share of profit after tax of Rs. 155.33 lacs, for the quarter ended 30th June 2026, as considered in the statement, in respect of one foreign associate, whose financial results have not been reviewed by us.
   These financial results are certified by the management of respective companies and our conclusion on the Statement in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate

DOOGAR & ASSOCIATES FRN: 000561N New Delhi Chartered Accountants is based solely on the basis of financial statement as certified and procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of above matter.

We did not review the Consolidated Financial Statement of one foreign subsidiary namely Poly Medicure BV Netherlands for the quarter ended 30th June 2026, which includes financial statements of Plan 1 Health SRL Italy for quarter ended 31 March 2026 and whose financial statement without elimination reflect total revenue of Rs. 2838.09 lacs, Net profit after tax of Rs. 192.06 lacs and total comprehensive income/ (loss) of Rs. 192.06 lacs for the quarter ended 31 March 2026 and have been limited reviewed by auditor situated outside India and also includes financial statement of Poly Health Medical Inc. US, Poly Health Limited UK, Risor Holding B.V. Netherlands (consolidated) and Medistream SA Switzerland (consolidated), whose financial statement without elimination reflect total revenue of Rs. 8,474.45 lacs, total profit/ (loss) after tax of Rs. (418.00) lacs and total comprehensive income/ (loss) of Rs. (418.00) lacs for the quarter ended 30 June 2026 and have been management certified and given effect to in consolidated financial statements. Our opinion on consolidated financial statements in so far as it relates to the aforesaid subsidiary is based on limited review report of one step down subsidiary and management certified financial statements of other step down subsidiaries. Our conclusion on the statement is not modified in respect of above matter.

7. In respect of subsidiaries and associate located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and are management certified/ limited reviewed. The Parent's management has converted the financial results of such subsidiaries and associate located outside India from accounting principles generally accepted in their respective countries to the accounting principles generally accepted in India. We have reviewed conversion adjustments made by the parent's management. Our conclusion in so far as it relates to balances and affairs of such subsidiaries and associate located outside India is based on the conversion adjustments prepared by the management of the Parent and reviewed by us.

8. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial statements as limited reviewed/ certified by the management referred to paragraph 6 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid in the aforesaid Indian Accounting Standard specified under Section 133 of Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm's Registration number: 000561N

DOOGAR & ASSOCIATES FRN: 000561N New Delhi Chartered Accountants

Madhusudan Agarwal
Partner
Membership number: 086580
UDIN: 26086580JKHWP15759

Place: Jaipur
Date: 07 August 2026

Annexure – 1

List of entities included in the consolidated financial statements for the quarter ended 30th June, 2026 are as under:

Sr. No.	Name of the Company	Country of incorporation
	Parent Company	
1	Poly Medicure Limited	
	Subsidiary	
2	Plan 1 Health India Private Limited[1]	India
3	Poly Medicure (Laiyang) Company Limited[1]	China
4	Poly Medicure B.V.[1]	Netherlands
5	Polymed Brazil LTDA[1]	Brazil
6	Himalayan Mineral Waters Private Limited[1]	India
	Step - subsidiary	
7	Plan 1 Health SRL[2]	Italy
8	Risor Holding B.V.[2]	Netherlands
9	Wellinq Medical B.V.[3]	Netherlands
10	Pendracare Holding B.V.[3]	Netherlands
11	Pendracare Vascular B.V.[4]	Netherlands
12	Pendracare International B.V.[4]	Netherlands
13	Medistream SA[2]	Switzerland
14	Citieffe SRL[5]	Italy
15	Citieffe Inc.[6]	USA
16	Citieffe De.[6]	Mexico
17	Poly Health Inc.[2]	USA
18	Poly Health Limited[2]	UK
19	Medyneo Comercio De Produtos Para Saude LTDA[7]	Brazil
	Associate	
20	Ultra For Medical Products Company (Ultra Med)	Egypt

[1] Wholly-owned subsidiary of Poly Medicure Limited
[2] Wholly-owned subsidiary of Poly Medicure B.V.
[3] Wholly-owned subsidiary of Risor Holding B.V.
[4] Wholly-owned subsidiary of Pendracare Holding B.V.
[5] Wholly-owned subsidiary of Medistream SA
[6] Wholly-owned subsidiary of Citieffe SRL
[7] Wholly-owned subsidiary of Polymed Brazil LTDA

DOOGAR & ASSOCIATES
FRN: 000561N
New Delhi
Chartered Accountants

Annexure – B

DISCLOSURE AS PER LISTING REGULATIONS READ WITH SEBI CIRCULAR NO .SEBI/HO/CFD/PoD2/CIR/P/0155 DATED NOVEMBER 11, 2024 AND DECEMBER 31, 2024

Grant of Stock Option

Sr. No.	Particulars	Remarks
1.	Brief details of Options Granted	1,476 Options granted by the Nomination & Remuneration Committee in its meeting held on today i.e. on August 07, 2026) to the Employees as defined under the Scheme.
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021	Yes
3.	Total number of shares covered by these options	Stock Options granted under the aforesaid Grant covers 1,476 Equity Shares. 1 Option shall be entitled for conversion to only 1 Share of the Company, subject to the terms of the Scheme.
4.	Pricing formula	Pursuant to the applicable provisions of the SEBI (SBEB) Regulations 2021 and as per provisions of the existing 'ESOP Plan', the ESOPs have been granted at a price of INR 100/- i.e. discounted price to the latest available closing price prevailing on the Stock Exchange on Friday, August 07, 2026.
5.	Options Vested	Not Applicable
6.	Time within which option may be exercised	Exercise period shall not exceed 3 (Three) months from relevant Vesting date and the date after which the Options shall lapse, unless the said period is extended by the Committee in exceptional circumstances. The Options shall not Vest for a period of one year from the date of Grant. Upon the expiry of one year, the Vesting of Options shall take place over a maximum term of (4) four years as per the Scheme.
7.	Options exercised	Not Applicable

8.	Money realized by exercise of Options	Not Applicable
9.	The total number of shares arising as a result of exercise of option	Not Applicable
10.	Options lapsed	Not Applicable
11.	Variation of terms of Options	Not Applicable
12.	Brief details of significant terms	The Employee Stock Option Scheme is administered by the Nomination and Remuneration Committee of the Company. The grant of Options is based upon the eligibility criteria as mentioned in the Scheme. The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Scheme.
13.	Subsequent changes or cancellation or exercise of such options	Not Applicable
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options.	Not Applicable

Annexure - C

Regulation 10(c)

Certified true copy of Notification for issue of shares under Regulation 10 (c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

S. No	Particulars	Information
1	Company Name and Address of Registered Office	Poly Medicure Limited and Registered Office Address: 232B, Third Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020

2	Name of the Exchange on which the Company's shares are listed	Bombay Stock Exchange (BSE) and National Stock Exchange (NSE)
3	Filing date of the Statement referred in clause 22.1 b of guidelines with Stock Exchange	16.12.2022
4	Filing Number, if any	164383
5	Title of the Stock Option Scheme pursuant to which shares are issued, if any	Employee Stock Option Scheme, 2020
6	Kind of Security to be listed	Equity Shares
7	Par value of the Shares	Rs. 5/- each
8	Date of issue of shares	August 07, 2026
9	Number of shares issued	1,975 Equity Shares
10	Share certificate no, if applicable	NOT APPLICABLE
11	Distinctive number of the shares, if applicable	From 101359491 to 101361465
12	ISIN Number of the shares if issued in Demat	INE205C01021
13	Exercise Price per shares	Rs. 100/- per share
14	Premium per share	Rs. 95/- per share
15	Total issue shares after this issue	Equity Shares: - 10,13,61,465
16	Total issue Share Capital after this issue	Equity Shares: - 50,68,07,325
17	Detail of any lock-in on the shares	N.A
18	Date of expiry of lock-in	N.A
19	Whether shares incidental in all respects to existing shares, if not, when they become identical?	The shares are incidental in all respects to existing shares.
20	Details of Listing Fee, payable	N.A

Annexure- D

REQUIRED DISCLOSURES/DETAILS UNDER REGULATION 30 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGULATIONS") READ WITH APPLICABLE SEBI CIRCULAR

Appointment of Cost Auditor(s)

S.No.	Particular	M/s. Jai Prakash & Company, Cost Accountants
1.	Reasons for change viz appointment/ reappointment,	**Re-Appointment**
2.	Date of Appointment/ Re-appointment & term of appointment/ reappointment	Re-appointment of M/s. Jai Prakash & Company, Cost Accountants for the Financial Year 2026-27.
3.	Brief Profile (in case of appointment)	M/s Jai Prakash & Co, Cost Accountant firm was established in year 2006. The firm is managed by Cost Accounting professionals with high integrity. We are a team of strongly motivated and young entrepreneurs. By applying modern management techniques, we ensure on-target delivery of our assignments. At present we are providing services to the Esteemed Companies belonging to various industries i.e. Pharmaceuticals, Iron & Steels, Auto Parts and Accessories, Electrical & Electronics, Engineering, Chemicals, Textiles, Construction, Rubbers, Railways.
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA

Annexure - E

REQUIRED DISCLOSURES/DETAILS UNDER REGULATION 30 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGULATIONS") READ WITH APPLICABLE SEBI CIRCULAR

Details of cessation of Mr. Ravi Prakash as Deputy Company Secretary and Compliance Officer of the Company

S.No.	Particular	Details
1.	Reasons for change viz ~~appointment/reappointment~~, resignation, ~~removal, death or otherwise~~	Resignation Mr. Ravi Prakash has tendered his resignation from the position of Deputy Company Secretary of the Company vide his letter dated 21.07.2026 to pursue an alternate career opportunities outside the Organization.
2.	Date of ~~appointment/ reappointment/~~ cessation (as applicable) ~~& term of appointment/re-appointment~~	10.08.2026
3.	Brief Profile (in case of appointment)	NA
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA

Date: 21.07.2026

To,

The Team Manager,
Poly Medicure Limited
232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi-110020

I hope you are all doing well.

Please accept this email as my formal resignation from my position, effective today.

As per my employment terms, my notice period is two months. However, due to personal reasons, I request your consideration for a shorter notice period and kindly request to be relieved from my duties by **10 August 2026**.

I sincerely appreciate the opportunities, guidance, and support I have received during my time with the team. Working alongside all of you has been a valuable experience, and I am grateful for the learning and professional growth.

I will ensure a smooth transition by completing my pending responsibilities and providing all necessary handovers before my last working day. I kindly request your approval for my early release on **10 August 2026**.

Thank you for your understanding and support. Wishing the team continued success in all future endeavour's.

Thanks & Regards,

Ravi prakash

Ravi Prakash
Deputy Company Secretary